Tissue distribution of [14C]sucrose octasulfate following oral administration to rats.
OBJECTIVE
Aluminum sucrose octasulfate (SOS) is used clinically to prevent ulcers. Under physiologic conditions, the sodium salt of this drug can be formed. Our objective was to determine whether sodium SOS was absorbed when administered orally. In addition to furthering our understanding of aluminum SOS, this study also aimed to clarify how other polyanionic drugs, such as heparin and low-molecular-weight heparins, are absorbed.


METHODS
[14C]-labeled and cold sodium SOS (60 mg/kg) were given to rats by stomach tube. Radioactivity was counted in gut tissue, gut washes, and nongut tissue (i.e., lung, liver, kidney, spleen, endothelial, and plasma samples) at 3 min, 6 min, 15 min, 30 min, 60 min, 4 h, and 24 h, and in urine and feces accumulated over 4 h and 24 h.


RESULTS
Peak radioactivity was found in the tissue and washes of the stomach, ileum, and colon at 6 min, 60 min, and 4 h, respectively, showing progression through the gut. Gut recovery accounted for 84% of the dose at 6 min but only 12% of the dose at 24 h, including counts from feces. Radioactivity was recovered from nongut tissue (averaging 8.6% of the dose) and accumulated urine (18% of the dose at 24 h). When total body distribution was considered, the recovery of radioactivity was greater for the endothelium than for plasma (peak percentage of the dose was 65% at 15 min, 20% at 3 min, 5% from 20 to 240 min for the vena cava, aortic endothelium, and plasma, respectively).


CONCLUSIONS
Results indicate that sodium SOS is absorbed, agreeing with previous studies demonstrating the oral absorption of other sulfated polyanions. Endothelial concentrations must be considered when assessing the pharmacokinetics of these compounds. The measured plasma drug concentrations reflect the much greater amounts of drug residing with the endothelium.
Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada. linda.hiebert@usask.ca
Linda M
LM
Hiebert
Sandra M
SM
Wice
Tidly
T
Ping
Ronald E
RE
Hileman
Tfilay
T
Polat
Robert J
RJ
Linhardt
D000284:Administration, Oral; D000818:Animals; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013395:Sucrose / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics*; D014018:Tissue Distribution / Q000502:physiology
D002250:Carbon Radioisotopes; D013395:Sucrose; C053081:sucrose octasulfate